Final Terms for Medivir’s Voluntary Redemption Programme
January 30 2015 - 3:03AM
Business Wire
Regulatory News:
Medivir AB (STO:MVIRB) announces that the board of directors now
has set the final terms for Medivir’s voluntary redemption
programme. Every seventh share will be redeemable for a cash
consideration of SEK 140 per share.
The shareholders will receive one redemption right for each
share held in Medivir. Seven redemption rights entitle to
redemption of one share held. In total, a maximum amount of
SEK 625,200,380 may be paid as proceeds for the redeemed
shares.
The voluntary redemption programme, comprising a reduction of
the statutory reserve, a reduction of the share capital for
repayment to the shareholders and a bonus issue without issuance of
new shares, was resolved on at the extraordinary general meeting in
Medivir on 20 November 2014.
Below are the dates for the redemption programme. An information
brochure with additional information about the voluntary redemption
programme is available as from Monday 2 February 2015 on the
company’s website, www.medivir.se.
3 February 2015 Last day of trading in Medivir shares
including the right to receive redemption rights
5 February
2015 Record day for receiving redemption rights
6 February
2015 Distribution of the information brochure and the
application form to the company's directly registered shareholders
commences
10 February – 24 February 2015 Application period
for redemption
10 February – 20 February 2015 Period for
trading in redemption rights
10 February – 18 February 2015
Application period for commission-free sale of a maximum of 1,000
redemption rights
27 February – 6 March 2015 Period for
trading in redemption shares
Around 17 March 2015 Payment of
redemption proceeds
Medivir is required under the Securities Markets Act to make the
information in this press release public. The information was
submitted for publication at 8.30 CET on 30 January 2015.
About Medivir
Medivir is an emerging and profitable research‐based
pharmaceutical company with an established marketing and sales
organisation in the Nordic region with a broad portfolio of
prescription pharmaceuticals. Medivir receives royalties from
Johnson & Johnson on the global sales of the hepatitis C
pharmaceutical, OLYSIO®. In addition, revenues for sales of OLYSIO
in the Nordic region are generated through the company’s own sales
and marketing organisation. Medivir’s research and development
portfolio of pharmaceuticals is based on the company’s expertise
within protease inhibitor design and nucleoside/nucleotide science.
The company’s research and development focus is within infectious
diseases and oncology and the on-going clinical projects in
osteoarthritis and neuropathic pain. Medivir is listed on the
Nasdaq Stockholm Mid Cap List.
This information was brought to you by Cision
http://news.cision.com
Medivir ABRein Piir, EVP Corporate Affairs & IRmobile: +46
708 537 292orOla Burmark, newly appointed Chief Financial
Officer Medivir ABmobile: +46 (0)725 480580.